Posted from: Monday, October 09, 2017 - 05:49 PM - Present

Expanded Indication for Rapivab

September 21, 2017 – The U.S. FDA has approved an expanded indication for Rapivab® (peramivir injection), manufactured by BioCryst Pharmaceuticals, to treat acute, uncomplicated influenza (flu) in patients as young as two years old who have had flu symptoms for no more than 48 hours. Rapivab is delivered via intravenous (IV) injection as a single dose over the course of 15 minutes or longer. This provides an alternative for patients unable to use an oral flu treatment. A neuraminidase inhibitor, Rapivab was previously FDA-approved for use in patients 18 years and older.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Monday, November 12, 2018 - 12:43 PM.